BBIO vs VLTO · rev $438.2M vs P/E 29, rev $5.50B
BridgeBio Pharma Inc (BBIO) versus Veralto Corporation (VLTO) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Veralto Corporation (VLTO) is a pollution & treatment controls company listed on US.
Latest reported BBIO revenue for 2026-06-30 was $438.2M. Net income was -$322.4M. BBIO currently screens at market cap $13.24B.
Latest reported VLTO revenue for 2025-12-31 was $5.50B. Net income was $940.0M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
BBIO currently screens at market cap $13.24B. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
Not investment advice. Open the BBIO and VLTO stock pages for the full models.
Not investment advice.